BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 14, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eribulin mesylate: Additional Phase III data

Additional data from the open-label, international Phase III EMBRACE trial in 762 patients showed that eribulin significantly increased OS vs. the physician's choice of therapy (13.1 vs.10.7 months, p=0.04). Eribulin also significantly increased ORR vs. physician's choice (12% vs. 5%, p=0.005), but non-significantly increased median PFS (3.7 vs. 2.3 months, p=0.09). The median duration of response was 4.1 months for...

Read the full 276 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >